Exchange: NASDAQ·Updated 07:57 PM EST

FLGT News

News
all
press releases
Fulgent Genetics (FLGT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Fulgent Genetics (FLGT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks
Fulgent Genetics (FLGT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Fulgent Genetics (FLGT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks
More News
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +86.15% and +4.77%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2026. Third Quarter 2026 Results...
Business Wire
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2026 financial results after the market closes on Thursday...
Business Wire
Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.
Zacks
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -26.09% and -9.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Results: Revenue...
Business Wire
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2026 financial results after the market closes on Thursday...
Business Wire
Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO...
Business Wire

Advertisement|Remove ads.